FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012804955> ?p ?o ?g. }

• W2012804955 endingPage "17" @default.
• W2012804955 startingPage "1" @default.
• W2012804955 abstract "BACKGROUND There is increasing evidence that the stringent selective pressure imposed by androgen ablation therapy on the residual prostate cancer cells may actually accelerate the development of the hormone refractory and bone metastatic phenotype. The propensity of prostate cancer to establish osseous metastases is very likely mediated by the osteomimetic properties of the prostate cancer cells. Prostate cancer cells acquire these “bone-like” properties in order to survive in the bony microenvironment. This process is facilitated by common growth factor trophisms between the bone stromal cells, osteoblasts, and the prostate cancer cells wherein a number of growth factors and their receptors are involved. Thus, a general inhibition of the tyrosine kinase signaling pathways may have a therapeutic advantage in interfering with the metastatic potential of these prostate cancer cells. This study focuses on the potential of curcumin, a plant based non-toxic tyrosine kinase inhibitor in interfering with the development of bone like properties of C4-2B, a highly metastatic derivative of LNCaP prostate cancer cell line. METHODS C4-2B prostate cancer cells were analyzed for their constitutive expression and ligand inducible activation of growth factor receptors such as EGF-R and CSF1-R. Expression of bone-specific transcription factors such as Cbfa-1 and the production of PTHRP were followed. The ability of the C4-2B cells to mineralize under specific conditions was analyzed. The activation status of the transcription factor NF-κB was also followed. RESULTS Curcumin inhibited the ligand-stimulated autophosphorylation of EGF-R and CSF1-R that were crucially involved in the development of osteomimetic properties of C4-2B cells. When C4-2B cells were grown under promineralization conditions, curcumin prevented the formation of the mineralized nodules. It also inhibited the expression of the core-binding factor a-1 in C4-2B cells which was responsible for the expression of several bone-specific proteins. The IKK activity was severely impaired, showing marked NF-κB inhibition. The experiments indicate that curcumin can also interfere with the development of the osteoblast and the osteoclast-like properties by these prostate cancer cells. CONCLUSIONS The highly metastatic C4-2B prostate cancer cell line is already “programmed” to exhibit the bone-like properties that would at least in part explain its affinity to set up osseous metastases. Curcumin is able to interfere with the osteoblastic component as well as the osteoclastic component of this phenotype, by interfering with the growth factor receptor pathways and by inhibiting the NF-κB activation process. It is concluded that curcumin may inhibit the growth factor collaboration between the prostate cancer cells and the osteoblast/stromal cells, thus exhibiting a potential to prevent the establishment of bony metastases. © 2003 Wiley-Liss, Inc." @default.
• W2012804955 created "2016-06-24" @default.
• W2012804955 creator A5033346506 @default.
• W2012804955 creator A5039354344 @default.
• W2012804955 creator A5062259152 @default.
• W2012804955 creator A5089619585 @default.
• W2012804955 date "2004-06-15" @default.
• W2012804955 modified "2023-10-17" @default.
• W2012804955 title "Therapeutic potential of curcumin in prostate cancer?IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells" @default.
• W2012804955 cites W1524954611 @default.
• W2012804955 cites W175416543 @default.
• W2012804955 cites W1965402438 @default.
• W2012804955 cites W1967502057 @default.
• W2012804955 cites W1967897952 @default.
• W2012804955 cites W1968231448 @default.
• W2012804955 cites W1974359851 @default.
• W2012804955 cites W1974917142 @default.
• W2012804955 cites W1978960998 @default.
• W2012804955 cites W1985101923 @default.
• W2012804955 cites W1985727076 @default.
• W2012804955 cites W1987331822 @default.
• W2012804955 cites W1989808698 @default.
• W2012804955 cites W1994224526 @default.
• W2012804955 cites W1995341351 @default.
• W2012804955 cites W1998890155 @default.
• W2012804955 cites W2001544310 @default.
• W2012804955 cites W2011844120 @default.
• W2012804955 cites W2012865220 @default.
• W2012804955 cites W2015293591 @default.
• W2012804955 cites W2017757468 @default.
• W2012804955 cites W2018918471 @default.
• W2012804955 cites W2026790929 @default.
• W2012804955 cites W2033890749 @default.
• W2012804955 cites W2035522858 @default.
• W2012804955 cites W2044573147 @default.
• W2012804955 cites W2046510888 @default.
• W2012804955 cites W2046945256 @default.
• W2012804955 cites W2048639599 @default.
• W2012804955 cites W2053926227 @default.
• W2012804955 cites W2055184276 @default.
• W2012804955 cites W2056298416 @default.
• W2012804955 cites W2059085904 @default.
• W2012804955 cites W2063173329 @default.
• W2012804955 cites W2075172606 @default.
• W2012804955 cites W2082721745 @default.
• W2012804955 cites W2085691330 @default.
• W2012804955 cites W2086008590 @default.
• W2012804955 cites W2087324367 @default.
• W2012804955 cites W2087703443 @default.
• W2012804955 cites W2100214138 @default.
• W2012804955 cites W2100251566 @default.
• W2012804955 cites W2104500186 @default.
• W2012804955 cites W2104989681 @default.
• W2012804955 cites W2107601371 @default.
• W2012804955 cites W2114394594 @default.
• W2012804955 cites W2117963070 @default.
• W2012804955 cites W2139981029 @default.
• W2012804955 cites W2140473585 @default.
• W2012804955 cites W2146965174 @default.
• W2012804955 cites W2147921405 @default.
• W2012804955 cites W2151015976 @default.
• W2012804955 cites W2169595174 @default.
• W2012804955 cites W2169618540 @default.
• W2012804955 cites W227923971 @default.
• W2012804955 cites W2314325548 @default.
• W2012804955 cites W2318388129 @default.
• W2012804955 cites W2325349978 @default.
• W2012804955 cites W4230658001 @default.
• W2012804955 cites W4295115868 @default.
• W2012804955 cites W4298312879 @default.
• W2012804955 doi "https://doi.org/10.1002/pros.10359" @default.
• W2012804955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15129424" @default.
• W2012804955 hasPublicationYear "2004" @default.
• W2012804955 type Work @default.
• W2012804955 sameAs 2012804955 @default.
• W2012804955 citedByCount "56" @default.
• W2012804955 countsByYear W20128049552012 @default.
• W2012804955 countsByYear W20128049552013 @default.
• W2012804955 countsByYear W20128049552014 @default.
• W2012804955 countsByYear W20128049552015 @default.
• W2012804955 countsByYear W20128049552016 @default.
• W2012804955 countsByYear W20128049552017 @default.
• W2012804955 countsByYear W20128049552018 @default.
• W2012804955 countsByYear W20128049552019 @default.
• W2012804955 countsByYear W20128049552020 @default.
• W2012804955 countsByYear W20128049552021 @default.
• W2012804955 countsByYear W20128049552022 @default.
• W2012804955 countsByYear W20128049552023 @default.
• W2012804955 crossrefType "journal-article" @default.
• W2012804955 hasAuthorship W2012804955A5033346506 @default.
• W2012804955 hasAuthorship W2012804955A5039354344 @default.
• W2012804955 hasAuthorship W2012804955A5062259152 @default.
• W2012804955 hasAuthorship W2012804955A5089619585 @default.
• W2012804955 hasConcept C121608353 @default.
• W2012804955 hasConcept C126322002 @default.
• W2012804955 hasConcept C134018914 @default.
• W2012804955 hasConcept C16930146 @default.
• W2012804955 hasConcept C2776235491 @default.

• next